Introduction to HSYA Safety

Researchers recently conducted a comprehensive study to establish Hydroxysafflor Yellow A safety profiles using Sprague-Dawley rat models. This investigation is crucial because HSYA, derived from Safflower, is increasingly studied for its therapeutic potential in cardiovascular health. Consequently, understanding its developmental and reproductive impact is essential for future human applications. The study meticulously examined the toxicity across three distinct segments: Fertility and Early Embryonic Development (FEED), Embryo-Fetal Development (EFD), and Pre- and Postnatal Development (PPND).

During the experiments, the team administered HSYA intravenously at doses of 25, 75, or 250 mg/kg. In the highest dose group, the researchers noted a decrease in body weight for F0 males during the initial weeks post-administration. Additionally, some males exhibited temporary ocular secretions. However, these symptoms resolved by the seventh week, suggesting the effects were transient and manageable at specific dosage levels.

Implications for Hydroxysafflor Yellow A Safety

A major highlight of the research was the assessment of the F1 generation. Interestingly, the study found no significant differences in malformations or variations among the offspring. Furthermore, the survival rate of F1 offspring in the low-dose group was significantly higher than the control. This finding reinforces the overall Hydroxysafflor Yellow A safety margin for developmental outcomes. Toxicokinetic analysis also provided vital insights by confirming that HSYA successfully crosses both the placental and the blood-milk barriers. This movement highlights the need for careful dosing considerations in pregnant or lactating subjects.

Overall, the researchers determined the no-observed-adverse-effect level (NOAEL) for HSYA to be 250 mg/kg/day. This high threshold indicates a robust safety profile for the compound within the tested parameters. These results offer a valuable baseline for determining clinical dosing strategies in humans. Moreover, the data supports the ongoing transition of HSYA from traditional use to standardized pharmacological applications in modern medicine.

Frequently Asked Questions

Does HSYA affect fetal development?

The study found no significant malformations in the F1 generation. In fact, fetal body length in low-dose groups was greater than in controls, and survival rates remained high, suggesting a favorable developmental safety profile.

Can HSYA be passed from mother to infant?

Yes, toxicokinetic data confirmed that HSYA crosses both the placental barrier and the blood-milk barrier. This means the compound can reach the fetus and be present in breast milk.

What is the safe dosage level identified in this study?

The researchers identified the NOAEL (no-observed-adverse-effect level) as 250 mg/kg/day in Sprague-Dawley rats, providing a strong reference for human safety assessments.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding medical conditions or treatments. Refer to the latest local and national guidelines for clinical practice.

References

Qiu S et al. Developmental and reproductive toxicity studies of Hydroxysafflor Yellow a in Sprague-Dawley rats. Drug Chem Toxicol. 2026 Feb 21. doi: 10.1080/01480545.2026.2626758. PMID: 41722090.

Li CY et al. The Safety, Tolerability, and Pharmacokinetics of Active Ingredients From Hydroxysafflor Yellow A in Healthy Chinese Volunteers. Clin Pharmacol Drug Dev. 2025 Jan;14(1):79-86. doi: 10.1002/cpdd.1487.

Bai X et al. Therapeutic potential of hydroxysafflor yellow A on cardio-cerebrovascular diseases. Front Pharmacol. 2020;11:01265. doi: 10.3389/fphar.2020.01265.